Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
Become a Member | Sign in
Home>News>This Article

Purdue to Accelerate Drug Discovery, Development

Published: Monday, September 16, 2013
Last Updated: Monday, September 16, 2013
Bookmark and Share
Purdue Center for Drug Discovery adds to Purdue's strengths and the capacity to translate basic research into life-changing treatments.

Purdue President Mitch Daniels has highlighted how the center will create an innovative research and teaching environment to stimulate discovery and the translation of basic research into new ways to diagnose and treat disease.

"Here, as in other areas, we will seek to reinforce existing excellence," Daniels said. "Purdue has the proven talent, knowledge and drive to create new treatments and tools that improve health worldwide. Purdue researchers are already hard at work finding the connection between the molecular basis of disease and compounds to change the course of disease. Through Purdue's Center for Drug Discovery, we will accelerate the rate of drug discovery to move revelations from the lab to commercialization and then to the million of patients who need hope and relief."

The Purdue Center for Drug Discovery supports more than 100 faculty in six colleges and its research will focus on four disease categories: cancer; diabetes, obesity and cardiovascular; immune and infectious disease; and neurological disorders and trauma.

Joining Daniels at the forum were Philip Low, the Ralph C. Corley Distinguished Professor of Chemistry and inaugural director of the center, and Timothy Ratliff, professor and the Robert Wallace Miller Director of the Purdue University Center for Cancer Research. Ratliff, Low and directors of other Purdue centers with research focused on the disease targets will meet regularly to share discoveries and ensure a unified, efficient progression of the research.

"This new Purdue center will advance the level of research among our faculty and the educational experience of our research-driven and entrepreneurially focused undergraduate and graduate students," Low said. "It will encourage collaboration. It will bring people and their distinctive talents together, accelerating our rates of discovery and translation. And it sends the message to the world that Purdue University is committed to excellence in the field of drug discovery and development."

Purdue has strengths along all of the points of the drug discovery pipeline, including a premier structural biology group with a track record of discovering new targets to block disease, a chemistry department that has produced two Nobel laureates and is a leader in structure-based drug design, and top-ranked engineering and pharmacy programs, Ratliff said.

"Purdue has all the fundamentals and a history of getting things done - including more than 30 compounds at various stages of clinical development," he said. "If we build on this strength and put infrastructure in place to overcome the remaining challenges, the university can bring many more potentially life-changing or life-saving drugs to the clinic."

In addition, 14 core units are in place to provide shared resources for analysis, screening, synthesis and testing of potential therapeutic compounds, he said.

"We don't want any potential new treatment to fail because there isn't a resource to move it forward," Ratliff said. "Perhaps the professor who made the discovery doesn't have the expertise for the next step in the process. We want to make it easy for one professor to pass the torch to another and to draw on the reserves of our talented research staff to finish the marathon of drug discovery in record time."

The new center will help increase funding from federal agencies and industry, Low said. In a time of reduced overall federal support, investment in drug discovery remains strong.

Purdue also will be in a unique position to capitalize on a trend by major pharmaceutical companies to outsource research and development to universities and biotechnology firms, he said. The industry spent $9.4 billion in outsourcing its R&D in 2011, Kalorama Information reports.

"Purdue is among an elite handful of universities that are very productive in this area, and we are well-positioned to partner with the pharmaceutical industry and become a world leader in drug discovery," Low said.

Estimates also show that it costs approximately $1.4 billion and takes 10 years to bring a new prescription drug to the market, and pharmaceutical companies want to be confident in a drug candidate before pursuing it. That means compounds already through early testing and validation are much more competitive, Low said.

"Taking a discovery further along the drug development path, which is what this center is all about, is much more lucrative for the researcher and the university," he said. "The greatest return on research investment is right after establishing a 'proof of principle,' and taking a discovery through to this point means the difference between thousands and millions of dollars for the university. These revenues represent money that can be put back into discovery research and, thereby, further enhance our potential to change the world."

Other goals of the Purdue Center for Drug Discovery, which will be a part of Discovery Park and located in a state-of-the-art facility opening next spring in the Life and Health Sciences Park on the south end of campus, include:

* The center advances Purdue's primary mission to move discoveries from the laboratories to benefit citizens. This will be accomplished as Purdue researchers translate discoveries into the clinic, and then into commercial use, and through training courses in the development of startup companies, all of which will contribute to the state's economy.
* Advancing its role as a research leader in this area, Purdue becomes even more competitive in gaining larger research grants from state and federal agencies such as the National Institutes of Health, National Science Foundation, the U.S. Department of Defense, and major foundations and philanthropic organizations.
* Cutting-edge facilities are a magnet for attracting leading faculty and top-tier students. This also accelerates efforts to develop a curriculum and a learning culture that focuses on all aspects of the drug discovery pipeline - from discovery and development to the patenting of technology and processes that can be commercialized for greater and immediate impact.

"Students will get to experience all parts of the drug discovery process and see what it takes to get all the way through," Ratliff said. "Our students also will have the opportunity to be trained for careers in very popular and in-demand areas."

More details on the initiatives will be provided by Daniels throughout the fall semester. The initiatives were selected and developed over several months of work that involved deans, faculty and others at the university. Purdue's trustees also have reviewed and given support for the program.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

New Technique Yields Drug, Biomedical Test Results in One Minute
Slug flow microextraction makes it possible to quickly detect the presence of drugs or to monitor certain medical conditions using only a single drop of blood or urine.
Tuesday, October 14, 2014
Purdue, Houston Methodist to Take Drug Discoveries from the Bench Top to the Bedside
The planned collaboration on research and educational initiatives includes clinical trials of drugs developed at Purdue.
Monday, March 17, 2014
New Imaging Technology Could Reveal Cellular Secrets
Researchers have married two biological imaging technologies, creating a new way to learn how good cells go bad.
Friday, April 26, 2013
Yeast Study Yields Potential for New Cholesterol, Anti-Fungal Drugs
While studying a mutant strain of yeast, Purdue University researchers may have found a new target for drugs to combat cholesterol and fungal diseases.
Thursday, February 28, 2013
MolecularHUB Gives Scientific Information on Fast-moving Diseases
A scientific gateway website that will provide molecular and genetic information on infectious and emerging diseases has been released by Purdue University.
Thursday, October 25, 2012
Gene's function May Give New Target for Cancer Drugs
Scientists have determined that a gene long known to be involved in cancer cell formation and chemotherapy resistance is key to proper RNA creation, and could one day lead to new therapies and drug targets.
Thursday, September 13, 2012
Biochip Helps Study Living Cells
The biochip could speed scientific research, which could accelerate drug development for muscle and nerve disorders.
Friday, November 10, 2006
Scientific News
Potential Target for Treatment of Autism
Grant of $2.4 million will support further research.
Sniffing Out Cancer
Scientists have been exploring new ways to “smell” signs of cancer by analyzing what’s in patients’ breath.
Inroads Against Leukemia
Potential for halting disease in molecule isolated from sea sponges.
Molecular ‘Kiss Of Death’ Flags Pathogens For Destruction
Researchers have discovered that our bodies mark pathogen-containing vacuoles for destruction by using a molecule called ubiquitin, commonly known as the "kiss of death."
A New Single-Molecule Tool to Observe Enzymes at Work
A team of scientists at the University of Washington and the biotechnology company Illumina have created an innovative tool to directly detect the delicate, single-molecule interactions between DNA and enzymatic proteins.
Milestone Single-Biomolecule Imaging Technique May Advance Drug Design
The first nanometer resolved image of individual tobacco mosaic virions shows the potential of low-energy electron holography for imaging biomolecules at a single particle level; a milestone in structural biology and a potential new tool for drug design.
Multi-Gene Test Enables Some Breast Cancer Patients to Safely Avoid Chemotherapy
A major study is providing the best evidence to date that a 21-gene test done on the tumor can identify breast cancer patients who can safely avoid chemotherapy.
Antidepressants Plus Blood-Thinners Slow Down Brain Cancer
EPFL scientists have found that combining antidepressants with anticoagulants slows down brain tumors (gliomas) in mice.
Diagnostics Breakthrough Brings Viral Sequencing to Doctors’ Toolkit
New screening tool produces up to 10,000-fold improvement in viral matches compared with traditional high-throughput methods.
New Virus Identified In Blood Supply
Scientists have discovered a new virus that can be transmitted through the blood supply.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos